Merrimack Pharmaceuticals Inc Quick Ratio (MACK) starting from the first quarter 2024 to first quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Merrimack Pharmaceuticals Inc  (NASDAQ: MACK)

Merrimack Pharmaceuticals Inc's Quick Ratio

MACK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2024, Quick Ratio fell to 10.77 above Merrimack Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 104 other companies have achieved higher Quick Ratio than Merrimack Pharmaceuticals Inc in first quarter 2024. While Quick Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 71 to 327.

Explain Quick Ratio?
How much Cash & cash equivalents MACK´s has?
What are MACK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MACK Quick Ratio (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1
Y / Y Current Liabilities Change 4796.76 % -25.13 % 10.04 % -6.8 % -17.91 %
Y / Y Cash & cash equivalent Change 1158.23 % -2.9 % 44.4 % 42.03 % 35.73 %
Quick Ratio MRQ 10.77 42.8 38.34 46.15 41.9
MACK's Total Ranking # 327 # 71 # 62 # 17 # 62
Seq. Current Liabilities Change 5041.04 % -10.55 % 19.95 % -11.23 % -21.39 %
Seq. Cash & cash equivalent Change 1193.3 % -0.15 % -0.34 % -2.23 % -0.2 %



Quick Ratio first quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 170
Overall Market # 327


Quick Ratio Statistics
High Average Low
46.15 10.48 0.16
(Jun 30 2023)   (Mar 31 2017)




Financial Statements
Merrimack Pharmaceuticals Inc's Current Liabilities $ 23 Millions Visit MACK's Balance sheet
Merrimack Pharmaceuticals Inc's Cash & cash equivalent $ 244 Millions Visit MACK's Balance sheet
Source of MACK's Sales Visit MACK's Sales by Geography


Cumulative Merrimack Pharmaceuticals Inc's Quick Ratio

MACK's Quick Ratio for the trailling 12 Months

MACK Quick Ratio

 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth 1137.35 % -11.46 % -2.93 % -15.07 % -24.8 %
Y / Y Cash & cash equivalent TTM Growth 360.83 % 26.54 % 39.62 % 25.69 % 12.63 %
Quick Ratio TTM 12.53 42.12 39.22 37.1 33.64
Total Ranking TTM # 2943 # 2074 # 2130 # 2253 # 2550
Seq. Current Liabilities TTM Growth 1228.37 % -7.57 % 2.35 % -1.55 % -4.95 %
Seq. Cash & cash equivalent TTM Growth 295.1 % -0.74 % 8.2 % 8.6 % 8.49 %

Quick ratio ranking by company, industry and sector >> Back to MACK Financial Strength Comparisons >> Go to Compare MACK Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q1 2024 to $22.67 millions, cumulative Quick Ratio decreased to 12.53 above the MACK average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 450 other companies have achieved higher Quick Ratio than Merrimack Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 2074 to 2943.

Explain Quick Ratio?
How much Cash & cash equivalents MACK´s has?
What are MACK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 451
Healthcare Sector # 910
Within the Market # 2943


trailing twelve months Quick Ratio Statistics
High Average Low
42.12 10.03 0.45
(Dec 31 2023)   (Mar 31 2017)




Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2024 MRQ Cash & cash equivalentMar 31 2024 MRQ Current Liabilities
Onkure Therapeutics Inc   29.44 $ 82.835  Millions$ 2.814  Millions
Ideaya Biosciences Inc   29.35 $ 698.772  Millions$ 23.809  Millions
Terns Pharmaceuticals Inc   27.26 $ 240.654  Millions$ 8.828  Millions
Royalty Pharma Plc  26.29 $ 872.000  Millions$ 33.165  Millions
Alto Neuroscience Inc   25.72 $ 205.895  Millions$ 8.006  Millions
Keros Therapeutics Inc   23.64 $ 442.443  Millions$ 18.718  Millions
Disc Medicine Inc   23.07 $ 342.615  Millions$ 14.852  Millions
Arca Biopharma Inc  22.71 $ 35.903  Millions$ 1.581  Millions
Novabridge Biosciences  22.70 $ 173.398  Millions$ 7.638  Millions
Aprea Therapeutics Inc   22.07 $ 32.370  Millions$ 1.467  Millions
Milestone Pharmaceuticals Inc   21.67 $ 89.481  Millions$ 4.130  Millions
Oric Pharmaceuticals Inc   20.83 $ 316.778  Millions$ 15.210  Millions
Ventyx Biosciences Inc   20.82 $ 302.582  Millions$ 14.534  Millions
60 Degrees Pharmaceuticals Inc   20.71 $ 24.415  Millions$ 1.179  Millions
Cybin Inc   20.70 $ 160.088  Millions$ 7.734  Millions
Nuvalent Inc   20.70 $ 691.837  Millions$ 33.427  Millions
Contineum Therapeutics Inc   20.47 $ 117.907  Millions$ 5.760  Millions
Dyne Therapeutics Inc   20.28 $ 453.547  Millions$ 22.363  Millions
Kiora Pharmaceuticals Inc   20.24 $ 31.276  Millions$ 1.545  Millions
Annexon Inc   20.17 $ 264.948  Millions$ 13.133  Millions
Fulcrum Therapeutics Inc   19.95 $ 213.314  Millions$ 10.694  Millions
Ocular Therapeutix Inc   19.87 $ 482.888  Millions$ 24.298  Millions
Nkarta Inc   19.71 $ 437.394  Millions$ 22.189  Millions
Verve Therapeutics Inc   19.38 $ 606.367  Millions$ 31.294  Millions
Medicinova Inc   18.78 $ 47.139  Millions$ 2.511  Millions
Verona Pharma Plc  18.66 $ 254.882  Millions$ 13.656  Millions
Structure Therapeutics Inc   18.50 $ 436.449  Millions$ 23.586  Millions
Diamedica Therapeutics Inc   18.38 $ 46.516  Millions$ 2.531  Millions
Larimar Therapeutics Inc   17.70 $ 227.296  Millions$ 12.841  Millions
Ligand Pharmaceuticals Incorporated  17.43 $ 310.593  Millions$ 17.818  Millions

Date modified: 2026-09-12T06:14:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.